ArcticZymes AS, a subsidiary of Biotec Pharmacon ASA, has received an acceptance for the South African patent application covering its heat-labile DNase product.
With the approval of a new patent in South Africa, ArcticZymes is adding a new patent family with approved patents to its existing intellectual property portfolio. Additional patent applications are pending in the main markets including Europe, USA and Japan. The allowed patent provides for broad protection, covering amongst others the DNase product itself, its use, and kits including the DNase.
"This latest patent approval secures our existing position and opens new markets for our highly innovative products. The first approval is a strong indication that other patents in this patent family will follow, forming a strong fundament for our commercial efforts in the field,” says CEO Svein Lien in Biotec Pharmacon.
ArcticZymes develops, produces and sells enzymes used in molecular DNA technologies and diagnostics, growth...